2,4,6-trisubstituted 1,3,5-triazines as modulators of cx3cr1

A compound of formula (I)

• wherein
• R1 is a C3-6 branched alkyl or C3-6 branched haloalkyl;
• R2 is a C1-3 alkyl or C1-3 haloalkyl;
• m is 1 or 2;
• R3 and R4 are, independently, selected from H, halo, C1-3 alkyl, and C1-3 haloalkyl;
• A is phenyl, monocyclic heteroaryl, bicyclic aryl, or bicyclic heteroaryl;
• p is 0, 1, 2, 3, or 4;
• each R5 is independently selected from halo, hydroxy, oxo, C1-3 alkyl, C1-3 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, C1-4 alkoxy-C1-3alkyl, C1-3 hydroxyalkyl, —CN, —(CH2)qCN, —C(O)NR6R7, —NS(O)R6R7, —(CH2)qR8, —C(O)R9, —C(O)OR9, —OC(O)R9, —NR6C(O)R7, —NR6R7, C3-6 cycloalkyl, 4-6 member heteroaryl, 4-6 member heterocyclyl, and phenyl,
• wherein
• the C3-6 cycloalkyl or 4-6 member heterocyclyl can be optionally substituted with 1 to 3 substituents selected from hydroxy, oxy, halo, and —C(O)OR9,
• the 4-6 member heteroaryl can be optionally substituted with 1 to 3 halo substituents,
• the C1-4 alkoxy can be optionally substituted with a 4-6 member heterocyclyl,
• each R6 and R7 are, independently, selected from H and C1-3 alkyl,
• each q is, independently, 1, 2, or 3,
• each R8 is, independently a 4-6 member heterocyclyl, wherein the heterocyclyl is optionally substituted with a oxy, and
• each R9 is, independently, a C1-5 alkyl;
• or a pharmaceutically acceptable salt or tautomer thereof.